1. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

2. Program Goals

3. PAH Challenges Remain in 2016

5. Pharmacologic Agents for PAH 3 Pathways

6. Evidence-Based Guidelines

7. Risk Stratification

8. Treatment Algorithm for PAH

9. Monotherapy Recommendations for PAH

10. Initial Combination Therapy Recommendations for PAH

11. The Rationale for Combination Therapy

12. Recommendations for Sequential Combination Therapy

13. SERAPHIN Placebo vs Macitentan 3 mg vs Macitentan 10 mg (1:1:1)

15. Incident and Prevalent Treatment-Naïve Cohorts From SERAPHIN

16. What Can We Learn From the Treatment Naïve Patients in SERAPHIN?

17. In Conclusion

18. Abbreviations

19. Abbreviations